Biotech Insider Buying: Insys Therapeutics Inc (NASDAQ:INSY), Seattle Genetics, Inc. (NASDAQ:SGEN), Corcept Therapeutics Incorporated (NASDAQ:CORT), Durata Therapeutics Inc (NASDAQ:DRTX)

Insys Therapeutics Inc (NASDAQ:INSY), Director John N. Kapoor purchased 20,000 shares of the company’s stock on the open market in a transaction dated Wednesday, June 11th. The stock was purchased at an average cost of $24.54 per share, for a total transaction of $490,800.00. Following the purchase, the director now directly owns 15,991 shares in the company, valued at approximately $392,419. Insys Therapeutics Inc (NASDAQ:INSY), net profit margin is 36.90% and weekly performance is -0.69%. On last trading day company shares ended up $25.85. Analysts mean target price for the company is $52.50. Insys Therapeutics Inc (NASDAQ:INSY), distance from 50-day simple moving average (SMA50) is -21.27%.

Seattle Genetics, Inc. (NASDAQ:SGEN), Director Felix Baker bought 546,252 shares of the stock on the open market in a transaction dated Monday, June 9th. The shares were purchased at an average price of $38.16 per share, for a total transaction of $20,844,976.32. Following the transaction, the director now directly owns 76,997 shares in the company, valued at approximately $2,938,206. Seattle Genetics, Inc. (NASDAQ:SGEN), fell 0.02% in last trading session and ended the day on $40.09. SGEN, Gross Margin is 91.70% and its return on assets is -13.10%. Seattle Genetics, Inc. (NASDAQ:SGEN), quarterly performance is -20.28%.

Corcept Therapeutics Incorporated (NASDAQ:CORT), Director Joseph C. Cook, Jr. acquired 100,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, May 13th. The stock was purchased at an average price of $1.84 per share, with a total value of $184,000.00. Following the transaction, the director now directly owns 2,040,826 shares of the company’s stock, valued at approximately $3,755,120. Corcept Therapeutics Incorporated (NASDAQ:CORT), shares moved down 5.04% in last trading session and was closed at $2.45, while trading in range of $2.38 – 2.70. Corcept Therapeutics Incorporated (NASDAQ:CORT), year to date (YTD) performance is -18.40%.

Durata Therapeutics Inc (NASDAQ:DRTX), Director Schutter Richard De bought 15,000 shares of the company’s stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average cost of $15.57 per share, with a total value of $233,550.00. Following the completion of the purchase, the director now directly owns 15,000 shares of the company’s stock, valued at approximately $233,550. Durata Therapeutics Inc (NASDAQ:DRTX), ended the last trading day at $15.70. Company weekly volatility is calculated as 4.30% and price to cash ratio as 10.05. Durata Therapeutics Inc (NASDAQ:DRTX), showed a negative weekly performance of 2.06%.